A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

July 5, 2018

Study Completion Date

July 5, 2018

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Olaratumab

Administered IV

DRUG

Doxorubicin

Administered IV

RADIATION

External Beam Radiotherapy

Trial Locations (14)

20133

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milan

28203

Levine Children's Hospital, Charlotte

33612

Moffitt Cancer Center & Research Inst, Tampa

33701

All Children's Hospital, St. Petersburg

37232

Vanderbilt University Medical Center, Nashville

41013

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville

63110

Washington University Medical Center, St Louis

66210

Kansas City Cancer Center, Overland Park

69373

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon

75230

Mary Crowley Cancer Research, Dallas

90033

USC/Norris Comp Cancer Center, Los Angeles

06520

Yale University School of Medicine, New Haven

08025

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona

SW3 6JJ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02783599 - A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter